Cyteir Therapeutics, Inc. (CYT)
After hours:
| Previous close | 3.0800 |
| Open | 3.0650 |
| Bid | 3.0600 x 1200 |
| Ask | 3.1400 x 1400 |
| Day's range | 3.0100 - 3.0800 |
| 52-week range | 1.1300 - 3.1000 |
| Volume | |
| Avg. volume | 137,606 |
| Market cap | 109.794M |
| Beta (5Y monthly) | 0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
Business WireOngoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
LEXINGTON, Mass., October 12, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer" (Poster: LB_A13) at the 2023
Business WireCyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
LEXINGTON, Mass., June 30, 2023--Cyteir Therapeutics, Inc. ("Cyteir" or the "Company") (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir’s Board of Directors has determined, after consideration of potential strategic alternatives, it is in the best interests of its shareholders to dissolve Cyteir, liquidate its assets following an orderly wind down of the Company’s operations, and return
Business WirePreliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
LEXINGTON, Mass., June 03, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors" (Abstract: 3099, Poster: 297) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting i
